目的吡罗昔康乳膏的研制及稳定性研究。
OBJECTIVE To study the preparation and stability of piroxicam cream.
目的吡罗昔康乳膏的制备及稳定性研究。
ObjectiveTo study the preparation of piroxicam cream and its stability.
目的考察吡罗昔康凝胶的体外经皮离子导入。
OBJECTIVE to investigate the transdermal iontophoresis of piroxicam gel in vitro.
目的：研究吡罗昔康包合物混悬液的鼻粘膜吸收。
Objective: To investigate the suspension of inclusion compound of piroxicam nasal absorption.
结论吡罗昔康乳膏性质稳定，达到了质量标准的要求。
CONCLUSION the property of piroxicam cream was stable and reached the standard of the quality requirements.
这些结果从细胞免疫方面为吡罗昔康能够防治胃癌提供了一定的实验依据。
Therefore, it provide experimental basis on the clinical use of Piroxicam to prevent gastric cancer.
结果：总有效率吡罗昔康组为90％，吲哚美辛组为77％（P＜0．05）。
RESULTS: The total effective rates were 90% for Pir and 77% for Ind (P<0.05).
吡罗昔康是一种用于治疗炎症的非类固醇抗炎药，该药物已上市多年并用于治疗多种疼痛症状。
Piroxicam is a NSAID, a medicine used to treat inflammation. It has been available on the market for many years and has been used in the treatment of many painful conditions.
此外，CHMP的结论还指出，含有吡罗昔康的药物不应再用于急性(短期)疼痛和炎症的治疗。
In addition, the CHMP has concluded that piroxicam-containing medicines should no longer be used for the treatment of acute (short-term) pain and inflammation.
欧洲药品管理局(emea)最近完成了有关非类固醇抗炎药(NSAID)吡罗昔康的安全性评价。
The European Medicines Agency (EMEA) has recently completed a review of the safety of the non-steroidal anti-inflammatory drug (NSAID) piroxicam.
结论：吡罗昔康贴片治疗急慢性疼痛多项疗效指标结果优于双氯芬酸乳胶，安全性与双氯芬酸乳胶相似。
CONCLUSION: Piroxicam patch shows better efficacy and similar safety in the treatment of acute and chronic pain in comparing with diclofenac.
此外，CHMP还增加了吡罗昔康某些禁忌症并强调了警告信息，以确保不用于那些出现副作用的高危患者。
In addition, the CHMP added some contraindications and strengthened warnings for piroxicam, to ensure that it is not used in patients who are at a higher risk of developing side effects.
该局人用药品委员会(CHMP)的结论认为，吡罗昔康的益处仍大于其风险，但是，基于安全方面的考虑，其应用仅限于某些特定的适应症。
The Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that piroxicam's benefits still outweigh its risks, but, based on safety grounds, only in certain, limited indications.
用于释放活性物质的复合物，该复合物将活性物质限制在血液循环中或其它地方，这种复合物的例子如吡罗昔康倍他环糊精复合物或尼古丁倍他环糊精复合物。
Complexes intended to release an activesubstance that is entrapped by the complex in the blood circulation orelsewhere. Examples of such complexes are e. g. piroxicam betadex or nicotinebetadex.
用于释放活性物质的复合物，该复合物将活性物质限制在血液循环中或其它地方，这种复合物的例子如吡罗昔康倍他环糊精复合物或尼古丁倍他环糊精复合物。
Complexes intended to release an activesubstance that is entrapped by the complex in the blood circulation orelsewhere. Examples of such complexes are e. g. piroxicam betadex or nicotinebetadex.
应用推荐